Aptamer Group (P0J.F,APTA.L) and Alphazyme, a Maravai LifeSciences (MRVI) company, have entered into a licensing agreement for a developed Optimer for use in hot-start PCR applications. Aptamer grants Alphazyme a non-exclusive licence for use of an enzyme-modulating Optimer in hot-start PCR and next-generation sequencing applications within Alphazyme's own products and services.
Aptamer will manufacture the Optimer for Alphazyme. The agreement provides worldwide rights to Alphazyme and includes royalty payments on sales of products, milestone payments, and a supply agreement for the manufacturing of the Optimer.
Shares of Aptamer were up 4% to GBp 0.8378 at LSE on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.